Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Abstract Background Central nervous system (CNS) brain metastasis of advanced non-small cell lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy comparison of two first-generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib as first-...

Full description

Bibliographic Details
Main Authors: Meng-Xia Li, Hao He, Zhi-Hua Ruan, Yu-Xi Zhu, Rong-Qing Li, Xiao He, Bao-Hua Lan, Zhi-Min Zhang, Guo-Dong Liu, Hua-Liang Xiao, Yan Wu, Bo Zhu, Ge Wang, Zhen-Zhou Yang
Format: Article
Language:English
Published: BMC 2017-04-01
Series:BMC Cancer
Subjects:
EGFR-TKIs
Erlotinib
Gefitinib
NSCLC
EGFR mutation
Online Access:http://link.springer.com/article/10.1186/s12885-017-3165-0

Internet

http://link.springer.com/article/10.1186/s12885-017-3165-0

Similar Items